DOCSLIB.ORG

Resveratrol Improves Cognition and Decreases Amyloid Plaque Formation in Tg6799 Mice

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Resveratrol Improves Cognition and Decreases Amyloid Plaque Formation in Tg6799 Mice MOLECULAR MEDICINE REPORTS 19: 3783-3790, 2019 Resveratrol improves cognition and decreases amyloid plaque formation in Tg6799 mice YUE CHEN1, GUANG-WEI SHI2, ZHI-MAN LIANG1, SHU-YUE SHENG2, YU-SHENG SHI3, LI PENG1, YA-PING WANG1,4, FANG WANG1 and XING-MEI ZHANG1 1Key Laboratory of Psychiatric Disorders of Guangdong Province, Department of Neurobiology, School of Basic Medical Sciences; 2The First Affiliated Hospital;3 Department of Radiation Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong 510515; 4Department of Rehabilitation, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong 510282, P.R. China Received May 12, 2018; Accepted September 29, 2018 DOI: 10.3892/mmr.2019.10010 Abstract. Alzheimer's disease (AD) is an irreversible, progres- Introduction sive neurodegenerative disorder of the central nervous system that causes severe cognitive impairment. One of the most Alzheimer's disease (AD) is a progressive neurodegen- significant pathological features of AD is the accumulation erative disorder characterized by cognitive and memory of β-amyloid (Aβ) peptide in the brain. Resveratrol (Res) is a impairments (1). There are >35 million individuals with AD polyphenol derived from peanuts, red grapes and other plants, worldwide, thus resulting in marked emotional and financial which has received increasing attention due to its neuropro- burdens on patients and society (2). The accumulation of tective features. Tg6799 mice are transgenic mice with five β-amyloid (Aβ) peptide in the brain is strongly implicated as familial AD (FAD) mutations that are also known as 5XFAD a main hallmark of sporadic and familial forms of AD (3,4). mice. The present study aimed to investigate the effects of Amyloid precursor protein (APP) -derived toxic peptides are Res on Tg6799 mice. The transgenic mice were randomly found at autopsy in the brains of individuals with AD (5). Aβ is divided into the Res treatment group and the vehicle control cleaved from APP by β-secretase 1 (BACE1) and subsequently group, and were treated with 0.5% Res solution (60 mg/kg) by γ-secretase. BACE1 is considered the rate-limiting enzyme or volume-matched normal saline, respectively. Treatment in the production of Aβ (6,7). In addition, accumulation of was administered by oral gavage daily for 60 consecutive BACE1 is observed in normal and dystrophic presynaptic days. Res reduced amyloid plaque formation and the levels terminals surrounding the amyloid plaques in brains of AD of Aβ42, and β-secretase 1 levels were also significantly mouse models and patients (8,9). decreased. Furthermore, Res was able to reduce the expres- The effects of medications that are currently approved by sion of amyloid precursor protein and its cleavage products. the USA Food and Drug Administration for the treatment of The administration of Res to Tg6799 mice also improved their AD manifestations are modest, transient and provide only spatial working memory, as measured by the Y-maze test, and symptomatic treatment (10). Recently, researchers have been rescued spatial memory deficits, as measured using the Morris paying more attention to herbal extracts for their potential water maze test; however, Res did not affect their motor func- therapeutic effects on AD. Resveratrol (Res) is a natural tion. In conclusion, this study suggested that Res may reduce polyphenol with strong effects, including anti-oxidative, Aβ-induced neuronal damage, thus preventing memory loss. anti‑inflammatory, cardiovascular protective, neuroprotective and cancer chemopreventive activities (11-13). It has been suggested that Res can act as a potent antioxidant in neurode- generative disorders. Previous studies have reported that Res has the ability to regulate Aβ toxicity or significantly increase the Aβ clearance rate in a mouse model of AD (14,15). Res can Correspondence to: Professor Fang Wang or Professor Xing-Mei also increase resistance against nerve inflammation and exerts Zhang, Key Laboratory of Psychiatric Disorders of Guangdong anti-oxidant effects that contribute to its neuroprotective Province, Department of Neurobiology, School of Basic Medical effects on the nervous system (16,17). Sciences, Southern Medical University, 1838 Guangzhou Avenue, Tg6799 mice are APP/presenelin 1 (PS1) double transgenic Guangzhou, Guangdong 510515, P.R. China E-mail: [email protected] mice that coexpress five familial AD (FAD) mutations, which E-mail: [email protected] are also known as 5XFAD mice. This mouse strain is a useful model of AD that recapitulates the relevant pathogenic features Key words: Alzheimer's disease, Tg6799 mice, resveratrol, amyloid of AD amyloid pathology. Intraneuronal Aβ42 accumulates in plaques, Y-maze test, Morris water maze the brain starting at 1.5 months, and the levels of brain Aβ42 and Aβ40 increase with age, whereas, the Aβ42/Aβ40 ratio decrease. Amyloid deposition starts at 2 months. Tg6799 mice 3784 CHEN et al: RESVERATROL IMPROVES COGNITION AND DECREASES AMYLOID PLAQUE FORMATION develop memory deficits by 4 months of age, as assessed using the time spent in the target quadrant and the speed were a Y-maze test compared with nontransgenic control mice (18). recorded using a video tracking system. The present study aimed to determine the protective effects and underlying mechanisms of Res in AD treatment. Thioflavin S staining. Four mice from each group were sacrificed with 0.75% pentobarbitone sodium (50 mg/kg) by Materials and methods intraperitoneal injection. The deeply anesthetized mice exhib- iting loss of reflexes and muscle relaxation were perfused with Animals and Res treatment. This study was approved 4% paraformaldehyde in PBS. Subsequently, the hippocampus by The Animal Ethics Committee of Nanfang Hospital, was extracted and frozen sections, measuring 35 µm in thick- Southern Medical University (application no. NFYY-2015-43; ness, were prepared at ‑25˚C. For thioflavin S immunostaining, Guangzhou, China). The experiments were performed using brain sections were allowed to defrost at room temperature male Tg6799 mice (Jackson Laboratory, Bar Harbor, ME, and were then washed with PBS for 5 min. The sections were USA), which express the human APP and PS1 genes and five then stained with freshly prepared 0.4% thioflavin S solution FAD mutations on a C57/B6XSJL background (18). These mice (Sigma-Aldrich; Merck KGaA) for 5 min in the dark at room were group-housed under standard environmental conditions temperature, washed twice for 3 min with 70% alcohol, washed (12-h light/dark cycle, 23±1˚C and 55±5% relative humidity), twice for 5 min with PBS and mounted. Image acquisition was with free access to food and water. The procedures were performed under a fluorescence microscope. Plaque counts performed in strict accordance with the National Institutes were quantified by counting thioflavin S‑positive plaques in of Health Guidelines for the Care and Use of Laboratory the hippocampus. The region of interest was manually selected Animals (19). At 2.5 months of age, 40 male Tg6799 mice under x4 magnification and all parameters were kept constant (weight, 18-22 g) were randomly divided into the control and during the analysis. Res groups (n=20/group). According to a previous study (20), the Res group was treated daily with 0.5% Res (Sigma-Aldrich; Aβ40 and Aβ42 ELISA. Another four mice from each group Merck KGaA, Darmstadt, Germany; 60 mg/kg/day) by oral were used to conduct Aβ ELISA analyses. Following Res gavage for 60 consecutive days, whereas the control group was treatment for 60 days, animals were anesthetized by pento- treated with volume-matched normal saline by gavage. barbitone sodium (50 mg/kg) and were decapitated. The required amount of homogenization buffer was prepared prior Behavioral testing to use. The hemisphere tissues (50 mg) were isolated and Open field test.The open field apparatus consisted of a rectan- homogenized using a Potter-Elvehjem homogenizer (DWK gular chamber (40x40x30 cm) made of gray polyvinyl chloride. Life Sciences, Millville, NJ, USA). Brain homogenates were A video camera, a loudspeaker that provided masking noise treated with PBS/protease inhibitor (Thermo Fisher Scientific, and a 25 W red light bulb (illumination density at the center Inc., Waltham, MA, USA) and were supplemented with guani- of the maze was 0.3 lx) were placed 180 cm above the center dine HCl to a final concentration of 5 mol/l. The brain tissue of the apparatus. The mice were gently placed at the center samples were then added to an Eppendorf tube containing and were allowed to explore the area for 5 min. The digitized the brain extraction buffer provided in the ELISA kits (cat. image of the path taken by each mouse was recorded and loco- nos. KHB3481, KHB3441 and KHB3442; Invitrogen; Thermo motor activity was subsequently analyzed using EthoVision Fisher Scientific, Inc.). The sample was ground thoroughly 7.0 software (Noldus Information Technology, Wageningen, with a tissue homogenizer, and then centrifuged at 16,000 x g The Netherlands). for 20 min at 4˚C. The supernatant was carefully transferred to a new tube and diluted with the buffer provided in the BioRad Y‑maze test. A black Y-maze was used with an arm length protein assay kit (Bio-Rad Laboratories, Inc., Hercules, CA, of 40 cm, width of 3 cm and wall height of 12.5 cm. Each USA). Final guanidine HCl concentrations were <0.1 mol/l. mouse was placed in the center of the symmetrical Y-maze The protein content was measured using the Bio-Rad protein and allowed to explore freely through the maze until they assay kit. Duplicate samples were subsequently analyzed entered the arms 22 times; the sequence of 22 entries was using Aβ40- and Aβ42‑specific sandwich colorimetric ELISA recorded. Each mouse was placed at the end of one arm facing kits (cat. nos. KHB3481, KHB3441 and KHB3442; Invitrogen; the center and its movements were recorded for 8 min. Data Thermo Fisher Scientific, Inc.), according to themanufacturer's were analyzed to determine the number of arm entries without protocol.
Load more

Recommended publications
  • Thioflavin Derivatives for Use in the Diagnosis of Alzheimer's Disease
    (19) TZZ Z__T (11) EP 2 264 018 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: C07D 277/66 (2006.01) C07D 277/64 (2006.01) 11.02.2015 Bulletin 2015/07 A61K 49/00 (2006.01) A61K 31/428 (2006.01) A61K 51/04 (2006.01) A61P 25/28 (2006.01) (2006.01) (21) Application number: 10185669.8 G01N 33/534 (22) Date of filing: 24.08.2001 (54) Thioflavin derivatives for use in the diagnosis of Alzheimer’s disease Thioflavinderivate zur Diagnose der Alzheimerschen Krankheit Dérivés de thioflavine pour le diagnostic de la maladie d’Alzheimer (84) Designated Contracting States: (72) Inventors: AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU • Klunk, William, E. MC NL PT SE TR Pittsburgh, PA 15218 (US) Designated Extension States: • Mathis, Chester, A., JR. AL LT LV MK RO SI Pittsburgh, PA 15238 (US) • Wang, Yanming (30) Priority: 24.08.2000 US 227601 P Imperial, PA 15126 (US) (43) Date of publication of application: (74) Representative: Plougmann & Vingtoft A/S 22.12.2010 Bulletin 2010/51 Rued Langgaards Vej 8 2300 Copenhagen S (DK) (62) Document number(s) of the earlier application(s) in accordance with Art. 76 EPC: (56) References cited: 01966165.1 / 1 334 091 WO-A-97/26919 WO-A1-01/14354 (73) Proprietor: University of Pittsburgh - Of the Commonwealth System of Higher Education Pittsburgh, PA 15260 (US) Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations.
    [Show full text]
  • Multimodal Imaging Gd-Nanoparticles Functionalized with Pittsburgh Compound B Or a Nanobody for Amyloid Plaques Targeting
    Multimodal imaging Gd-nanoparticles functionalized with Pittsburgh compound B or a nanobody for amyloid plaques targeting. Jonathan Pansieri, Marie Plissonneau, Nathalie Stransky-Heilkron, Mireille Dumoulin, Laurence Heinrich-Balard, Pascaline Rivory, Jean-François Morfin, Éva Tóth, Saraiva Maria Joao, Eric Allémann, et al. To cite this version: Jonathan Pansieri, Marie Plissonneau, Nathalie Stransky-Heilkron, Mireille Dumoulin, Laurence Heinrich-Balard, et al.. Multimodal imaging Gd-nanoparticles functionalized with Pittsburgh com- pound B or a nanobody for amyloid plaques targeting.. Nanomedicine, Future Medicine, 2017, 12 (14), pp.1675-1687. 10.2217/nnm-2017-0079. hal-01561318 HAL Id: hal-01561318 https://hal.archives-ouvertes.fr/hal-01561318 Submitted on 5 Feb 2021 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. Research Article For reprint orders, please contact: [email protected] 12 Research Article 2017/06/30 Multimodal imaging Gd-nanoparticles functionalized with Pittsburgh compound B or a nanobody for amyloid plaques targeting Jonathan Pansieri‡,1, Marie Nanomedicine (Lond.) Plissonneau‡,2,3, Nathalie Aim: Gadolinium-based nanoparticles were functionalized with either the Pittsburgh Stransky-Heilkron4, Mireille compound B or a nanobody (B10AP) in order to create multimodal tools for an early Dumoulin5, Laurence diagnosis of amyloidoses.
    [Show full text]
  • In Vitrocharacterization of Pittsburgh Compound-B Binding to Lewy Bodies
    The Journal of Neuroscience, September 26, 2007 • 27(39):10365–10371 • 10365 Neurobiology of Disease In Vitro Characterization of Pittsburgh Compound-B Binding to Lewy Bodies Michelle T. Fodero-Tavoletti,1,2,4 David P. Smith,1,4 Catriona A. McLean,5 Paul A. Adlard,4 Kevin J. Barnham,1,2,4 Lisa E. Foster,1 Laura Leone,1 Keyla Perez,1,2,4 Mikhalina Corte´s,4 Janetta G. Culvenor,1,3,4 Qiao-Xin Li,1,4 Katrina M. Laughton,1,4 Christopher C. Rowe,6 Colin L. Masters,1,4 Roberto Cappai,1,2,4 and Victor L. Villemagne1,4,6 1Department of Pathology, 2Bio21 Institute, and 3Centre for Neuroscience, The University of Melbourne, Melbourne, Victoria 3010, Australia, 4The Mental Health Research Institute of Victoria, Parkville, Victoria 3052, Australia, 5Department of Anatomical Pathology, Alfred Hospital, Prahran, Victoria 3181, Australia, and 6Centre for PET, Austin Hospital, Heidelberg, Victoria 3084, Australia Dementia with Lewy bodies (DLB) is pathologically characterized by the presence of ␣-synuclein-containing Lewy bodies within the neocortical, limbic, and paralimbic regions. Like Alzheimer’s disease (AD), A␤ plaques are also present in most DLB cases. The contri- bution of A␤ to the development of DLB is unclear. [ 11C]-Pittsburgh compound B ([ 11C]-PIB) is a thioflavin-T derivative that has allowed in vivo A␤ burden to be quantified using positron emission tomography (PET). [ 11C]-PIB PET studies have shown similar high cortical [ 11C]-PIB binding in AD and DLB subjects. To establish the potential binding of PIB to ␣-synuclein in DLB patients, we characterized the in vitro binding of PIB to recombinant human ␣-synuclein and DLB brain homogenates.
    [Show full text]
  • Vizamyl, INN-Flutemetamol (18F)
    26 June 2014 EMA/546752/2014 Committee for Medicinal Products for Human Use (CHMP) Vizamyl flutemetamol (18F) Procedure No. EMEA/H/C/002553 Marketing authorisation holder: GE HEALTHCARE LIMITED Assessment report for an initial marketing authorisation application Assessment report as adopted by the CHMP with all commercially confidential information deleted 30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5555 Send a question via our website www.ema.europa.eu/contact An agency of the European Union © European Medicines Agency, 2014. Reproduction is authorised provided the source is acknowledged. Table of contents 1. Background information on the procedure .............................................. 7 1.1. Submission of the dossier ...................................................................................... 7 1.2. Manufacturers ...................................................................................................... 8 1.3. Steps taken for the assessment of the product ......................................................... 8 2. Scientific discussion ................................................................................ 9 2.1. Introduction......................................................................................................... 9 2.2. Quality aspects .................................................................................................. 11 2.2.1. Introduction ...................................................................................................
    [Show full text]
  • Thioflavin-Positive Tau Aggregates Complicating Quantification
    www.nature.com/scientificreports OPEN Thiofavin‑positive tau aggregates complicating quantifcation of amyloid plaques in the brain of 5XFAD transgenic mouse model Jisu Shin, Sohui Park, HeeYang Lee & YoungSoo Kim* Transgenic mouse models recapitulating Alzheimer’s disease (AD) pathology are pivotal in molecular studies and drug evaluation. In transgenic models selectively expressing amyloid‑β (Aβ), thiofavin S (ThS), a fuorescent dye with β‑sheet binding properties, is widely employed to observe amyloid plaque accumulation. In this study, we investigated the possibility that a commonly used Aβ‑expressing AD model mouse, 5XFAD, generates ThS‑positive aggregates of β‑sheet structures in addition to Aβ fbrils. To test this hypothesis, brain sections of male and female 5XFAD mice were double‑stained with ThS and monoclonal antibodies against Aβ, tau, or α‑synuclein, all of which aggregates are detected by ThS. Our results revealed that, in addition to amyloid plaques, 5XFAD mice express ThS‑positive phospho‑tau (p‑tau) aggregates. Upon administration of a small molecule that exclusively disaggregates Aβ to 5XFAD mice for six weeks, we found that the reduction level of plaques was smaller in brain sections stained by ThS compared to an anti‑Aβ antibody. Our fndings implicate that the use of ThS complicates the quantifcation of amyloid plaques and the assessment of Aβ‑targeting drugs in 5XFAD mice. Alzheimer’s disease (AD) is defned by accumulation of amyloid-β (Aβ) plaques and neurofbrillary tau tangles in the brain, leading to neurodegeneration and cognitive dysfunction 1. Te need for deeper molecular under- standing underlying AD pathogenesis and the discovery of efective therapeutics has led to the development of transgenic mouse models mimicking Aβ and tau pathologies.
    [Show full text]
  • Characterizing Interactions of Thioflavin-T with Native Proteins
    Characterizing Interactions of Thioflavin-T with Native Proteins Especially Bovine Serum Albumin by Caleb Matthew Stratton April, 2017 Director of Thesis: Atta Ahmad (PhD) Major Department: Biology Abstract Thioflavin T is a fluorescent probe used to monitor formation of cross β-sheet rich amyloid fibrils. Involvement of the amyloid fibrils is implicated in more than 50 human diseases, such as Alzheimer’s, Parkinson’s and Prion’s. The proteins responsible for each of these diseases many as well as model proteins have been used to unravel the process involved in native protein to amyloid transformation, especially, for drug design but with little success thus far. Bovine serum albumin (BSA), predominantly α-helical in constitution, is one such protein that has been observed to transform to β-sheet rich amyloid. For our thesis project, we set on with these basic lines of evidence for ThT and BSA and devised a study outline. The study was divided into sub sections for better redressal compared to what was reported in literature viz., 1) Characterizing the steps involved in the transformation of BSA from native to amyloid state, 2) Develop methodology to gain information of as many steps as possible, 3) Identify the structural changes triggering BSA on pathway to fibrillation, 4) Computational comparison of the sites with chaperone binding sites and finally 5) if from point 4 we could observe chaperones interfering the aggregation process of BSA. During this thesis work, we observed an unexpected interaction of the reporter ThT molecule with the native BSA. We expanded this further and used a suite of standard proteins and found that ThT has the unlikely affinity to bind to some of the proteins, which are predominantly helical in nature.
    [Show full text]
  • Inhalable Thioflavin S for the Detection of Amyloid Beta Deposits
    molecules Article Inhalable Thioflavin S for the Detection of Amyloid Beta Deposits in the Retina Shawn M. Barton 1,2 , Eleanor To 3, Baxter P. Rogers 1,2,4,5 , Clayton Whitmore 1,2, Manjosh Uppal 3, Joanne A. Matsubara 3,* and Wellington Pham 1,2,4,6,7,8,9,10,* 1 Vanderbilt University Institute of Imaging Science, Vanderbilt University Medical Center, Nashville, TN 37232, USA; [email protected] (S.M.B.); [email protected] (B.P.R.); [email protected] (C.W.) 2 Department of Radiology and Radiological Sciences, Vanderbilt University Medical Center, Nashville, TN 37232, USA 3 Department of Ophthalmology and Visual Sciences, The University of British Columbia, Eye Care Center, Vancouver, BC V5Z 3N9, Canada; [email protected] (E.T.); [email protected] (M.U.) 4 Department of Biomedical Engineering, Vanderbilt University, Nashville, TN 37235, USA 5 Department of Psychiatry and Behavioral Sciences, Vanderbilt University Medical Center, Nashville, TN 37212, USA 6 Vanderbilt Brain Institute, Vanderbilt University, Nashville, TN 37232, USA 7 Vanderbilt Ingram Cancer Center, Nashville, TN 37232, USA 8 Vanderbilt Institute of Chemical Biology, Vanderbilt University, Nashville, TN 37232, USA 9 Vanderbilt Institute of Nanoscale Science and Engineering, Vanderbilt University, Nashville, TN 37235, USA 10 Vanderbilt Memory and Alzheimer’s Center, Vanderbilt University Medical Center, Nashville, TN 37212, USA * Correspondence: [email protected] (J.A.M.); [email protected] (W.P.) Abstract: We present an integrated delivery technology herein employing the aerosolized method to repurpose thioflavin S for imaging amyloid beta (Abeta) deposits in the retina as a surrogate of Abeta in the brain for early detection of Alzheimer’s disease.
    [Show full text]
  • Extracellular Amyloid Deposits in Alzheimer's and Creutzfeldt
    International Journal of Molecular Sciences Review Extracellular Amyloid Deposits in Alzheimer’s and Creutzfeldt–Jakob Disease: Similar Behavior of Different Proteins? Nikol Jankovska 1,*, Tomas Olejar 1 and Radoslav Matej 1,2,3 1 Department of Pathology and Molecular Medicine, Third Faculty of Medicine, Charles University and Thomayer Hospital, 100 00 Prague, Czech Republic; [email protected] (T.O.); [email protected] (R.M.) 2 Department of Pathology, First Faculty of Medicine, Charles University, and General University Hospital, 100 00 Prague, Czech Republic 3 Department of Pathology, Third Faculty of Medicine, Charles University, and University Hospital Kralovske Vinohrady, 100 00 Prague, Czech Republic * Correspondence: [email protected]; Tel.: +42-026-108-3102 Abstract: Neurodegenerative diseases are characterized by the deposition of specific protein aggre- gates, both intracellularly and/or extracellularly, depending on the type of disease. The extracellular occurrence of tridimensional structures formed by amyloidogenic proteins defines Alzheimer’s disease, in which plaques are composed of amyloid β-protein, while in prionoses, the same term “amyloid” refers to the amyloid prion protein. In this review, we focused on providing a detailed di- dactic description and differentiation of diffuse, neuritic, and burnt-out plaques found in Alzheimer’s disease and kuru-like, florid, multicentric, and neuritic plaques in human transmissible spongiform encephalopathies, followed by a systematic classification of the morphological similarities and differ- ences between the extracellular amyloid deposits in these disorders. Both conditions are accompanied by the extracellular deposits that share certain signs, including neuritic degeneration, suggesting a particular role for amyloid protein toxicity. Keywords: Alzheimer’s disease; Creutzfeldt–Jakob disease; Gerstmann–Sträussler–Scheinker syn- drome; amyloid; senile plaques; PrP plaques; plaque subtypes Citation: Jankovska, N.; Olejar, T.; Matej, R.
    [Show full text]
  • Imaging Technology for Neurodegenerative Diseases Progress Toward Detection of Specific Pathologies
    NEUROLOGICAL REVIEW Imaging Technology for Neurodegenerative Diseases Progress Toward Detection of Specific Pathologies Chester A. Mathis, PhD; William E. Klunk, MD, PhD; Julie C. Price, PhD; Steven T. DeKosky, MD dvances in neuroimaging over the past 2 decades are products of breakthroughs in imaging technology, developments of more powerful computers and image- processing software, and expanding knowledge in basic and clinical neuroscience. In addition to the insights into normal brain structure and function that such methods Aprovide and the information that can be gained from disease-related changes in structure and func- tion, the promise of achieving diagnostic specificity through neuroimaging lies with the potential identification of pathognomonic proteins. Recent advances in imaging ␤-amyloid plaques, one of the hallmarks of Alzheimer disease, offer such a technological breakthrough and the possibility for more efficient assessment of antiamyloid interventions as well as specific noninvasive diagnos- tic capabilities. Arch Neurol. 2005;62:196-200 In the last several decades of the 20th cen- and other pathological disturbances. Tech- tury and the first several years of the 21st, niques for the rapid assessment of blood research and the clinical application of flow advanced functional imaging and the neuroimaging have proceeded at a dizzy- localization of brain activity or function. ing and accelerating rate. Structural im- Magnetic resonance spectroscopy contin- aging was initially limited to skull and ues to develop as another method for the spine radiographs and subsequently to in- noninvasive assessment of brain metabo- ference about what was happening in the lism in development, aging, and disease. brain by analyzing the patterns of arte- The development of positron emis- rial, capillary, and venous blood flow on sion tomography (PET) has followed a cerebral angiography.
    [Show full text]
  • Modeling Neurodegenerative Disorders in Drosophila Melanogaster
    International Journal of Molecular Sciences Review Modeling Neurodegenerative Disorders in Drosophila melanogaster Harris Bolus 1, Kassi Crocker 2,3, Grace Boekhoff-Falk 3,* and Stanislava Chtarbanova 1,* 1 Department of Biological Sciences, University of Alabama, Tuscaloosa, AL 35487, USA; [email protected] 2 Genetics Graduate Training Program, School of Medicine and Public Health, University of Wisconsin–Madison, Madison, WI 53705, USA; [email protected] 3 Department of Cell and Regenerative Biology, School of Medicine and Public Health, University of Wisconsin–Madison, Madison, WI 53705, USA * Correspondence: grace.boekhoff@wisc.edu (G.B.-F.); [email protected] (S.C.) Received: 18 March 2020; Accepted: 21 April 2020; Published: 26 April 2020 Abstract: Drosophila melanogaster provides a powerful genetic model system in which to investigate the molecular mechanisms underlying neurodegenerative diseases. In this review, we discuss recent progress in Drosophila modeling Alzheimer’s Disease, Parkinson’s Disease, Amyotrophic Lateral Sclerosis (ALS), Huntington’s Disease, Ataxia Telangiectasia, and neurodegeneration related to mitochondrial dysfunction or traumatic brain injury. We close by discussing recent progress using Drosophila models of neural regeneration and how these are likely to provide critical insights into future treatments for neurodegenerative disorders. Keywords: Drosophila; neurodegeneration; neuroregeneration 1. Introduction: Drosophila as a Model System for Studies of Human Disease The common fruitfly Drosophila melanogaster has been used as a genetic model system for more than 100 years. Because Drosophila are inexpensive to maintain and reproduce rapidly, an enormous repertoire of genetic technologies has been created over the past century [1]. Drosophila possess extensive homology with humans at the genetic level making them a useful model for investigation of the cellular and molecular processes underlying development and disease [2].
    [Show full text]
  • Spectral Properties of Thioflavin T and Its Complexes with Amyloid Fibrils
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE Journal of Applied Spectroscopy, Vol. 70, No. 6, 2003 SPECTRAL PROPERTIES OF THIOFLAVIN T AND ITS COMPLEXES WITH AMYLOID FIBRILS ∗ E. S. Voropai,a M. P. Samtsov,a K. N. Kaplevskii,a A. A. Maskevich,b UDC 535.37 V. I. Stepuro,b O. I. Povarova,c I. M. Kuznetsova,c K. K. Turoverov,c A. L. Fink,d and V. N. Uverskiid,e Comparative analysis of the absorption and fluorescence spectra and fluorescence excitation spectra of thioflavin T (ThT) in various solvents and in the composition of amyloid fibrils has shown that ThT, when ex- cited in the region of the long-wavelength absorption band, fluoresces in the spectral region with a maximum at 478–484 nm. The appearance in aqueous and alcohol solutions of a fluorescence band with a maximum near 440 nm has been attributed to the presence in the composition of the ThT preparations of an impurity with an absorption band in the 340–350-nm range. The literature data showing that in glycerol ThT has a wide fluorescence spectrum with two maxima are due to the artifact connected with the use of a high concen- tration of the dye. It has been suggested that the cause of the low quantum yield of ThT aqueous and alcohol solutions is the breakage of the system of conjugated bonds due to the reorientation of the benzothiozole and benzaminic rings of ThT in the excited state with respect to one another. The main factor determining the high quantum yield of fluorescence of ThT incorporated in fibrils is the steric restriction of the rotation of the rings about one another under these conditions.
    [Show full text]
  • Internalized Tau Oligomers Cause Neurodegeneration by Inducing Accumulation of Pathogenic Tau in Human Neurons Derived from Induced Pluripotent Stem Cells
    14234 • The Journal of Neuroscience, October 21, 2015 • 35(42):14234–14250 Neurobiology of Disease Internalized Tau Oligomers Cause Neurodegeneration by Inducing Accumulation of Pathogenic Tau in Human Neurons Derived from Induced Pluripotent Stem Cells Marija Usenovic, Shahriar Niroomand, Robert E. Drolet, Lihang Yao, Renee C. Gaspar, Nathan G. Hatcher, Joel Schachter, John J. Renger, and Sophie Parmentier-Batteur Neuroscience, Merck Research Laboratories, West Point, Pennsylvania 19486 Neuronal inclusions of hyperphosphorylated and aggregated tau protein are a pathological hallmark of several neurodegenerative tauopathies, including Alzheimer’s disease (AD). The hypothesis of tau transmission in AD has emerged from histopathological studies of the spatial and temporal progression of tau pathology in postmortem patient brains. Increasing evidence in cellular and animal models supports the phenomenon of intercellular spreading of tau. However, the molecular and cellular mechanisms of pathogenic tau trans- mission remain unknown. The studies described herein investigate tau pathology propagation using human neurons derived from induced pluripotent stem cells. Neurons were seeded with full-length human tau monomers and oligomers and chronic effects on neuronal viability and function were examined over time. Tau oligomer-treated neurons exhibited an increase in aggregated and phos- phorylated pathological tau. These effects were associated with neurite retraction, loss of synapses, aberrant calcium homeostasis, and imbalanced neurotransmitter release. In contrast, tau monomer treatment did not produce any measureable changes. This work sup- ports the hypothesis that tau oligomers are toxic species that can drive the spread of tau pathology and neurodegeneration. Key words: Alzheimer’s disease; hiPSC neurons; neurodegeneration; pathology propagation; tau oligomer seeds Significance Statement Several independent studies have implicated tau protein as central to Alzheimer’s disease progression and cell-to-cell pathology propagation.
    [Show full text]